Deutsche Bank AG Trims Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Deutsche Bank AG reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 3.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 249,989 shares of the biotechnology company’s stock after selling 8,975 shares during the quarter. Deutsche Bank AG owned 0.18% of Arrowhead Pharmaceuticals worth $3,185,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ARWR. Wells Fargo & Company MN lifted its stake in Arrowhead Pharmaceuticals by 43.1% during the fourth quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company’s stock worth $1,182,000 after purchasing an additional 18,933 shares during the last quarter. Bank of Montreal Can lifted its stake in Arrowhead Pharmaceuticals by 13.3% during the fourth quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company’s stock worth $282,000 after purchasing an additional 1,759 shares during the last quarter. Raymond James Financial Inc. bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $651,000. Barclays PLC lifted its stake in Arrowhead Pharmaceuticals by 13.0% during the fourth quarter. Barclays PLC now owns 312,560 shares of the biotechnology company’s stock worth $5,876,000 after purchasing an additional 35,950 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Arrowhead Pharmaceuticals during the fourth quarter worth $1,629,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ARWR. Citigroup reduced their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 13th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 28th. Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Royal Bank Of Canada dropped their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR opened at $19.91 on Tuesday. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -15.55 and a beta of 0.94. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $27.34. The stock’s fifty day moving average is $16.77 and its 200-day moving average is $15.88.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same quarter last year, the business earned ($1.38) earnings per share. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Activity at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 9,389 shares of the firm’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $20.00, for a total transaction of $187,780.00. Following the transaction, the insider directly owned 262,122 shares of the company’s stock, valued at approximately $5,242,440. This trade represents a 3.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.